About Our TeamDelivering Benefit to Bone
Dr. Robert Young
PhD, MC, FRSC, FCIC, FCSPS
Merck Frosst B.C. Leadership Chair in Pharmaceutical Genomics and Drug Discovery at SFU. Chair CDRD, Division of Drug Design and Synthesis. Co-discoverer and developer of SingulairTM, VioxxTM, ArcoxiaTM, PervicoxTM, TredaptiveTM, and odanicatib (Pre-NDA for treatment of Post Menopausal Osteoporosis)
Dr. Pieter Cullis
Director of UBC Life Sciences Institute. Founding Director CDRD. Department of Biochemistry & Molecular Biology. Founder of Inex, Northern Lipids, Protiva, Lipex Biomembranes, Acuitas Therapeutics, Precision Nanosystems, Tekmira
Dr. Fabio Rossi
Canada Research Chair of Regenerative Medicine. Fellow & Professor, the Michael Smith Foundation for Health Research. Professor Dept of Medical Genetics. Discovered Technology Licenses to DiscoveRx. Co-Director of Biomedical Research Centre
Dr. Michael Underhill
Professor Cellular and Physiological Sciences. Co-founder of Corigen, Nexigen Therapeutics and Mesentech. Focused on Anabolic Retinoic Acid Receptor Modulators for Bone & Cartilage.
More than 30 years experience in the biopharmaceutical industry serving in senior executive and CEO positions in “blue-chip” biopharmaceutical companies in both Europe and North America. Range of responsibilities has encompassed: drug discovery, research, clinical development and regulatory submissions, through to sales and marketing.
Mesentech's Scientific AdvisorsDelivering Benefit to Bone
Dr. Michael Glogauer
*Full Professor, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto
*Board Certified Periodontist
Dr. Glogauer is a clinician scientist with more than 20 years of experience in providing clinical periodontal treatment and dental implant placement. His research is focused on the role played by neutrophils and macrophages in health and disease. His group also focuses on researching upon the various crucial mechanisms that lead to periodontal and bone destruction and developing novel approaches for rebuilding lost alveolar bone prior to dental implant placement.
Dr. Marc Grynpas
*Director Bone and Mineral Group, University of Toronto
*Professor, Department of Laboratory Medicine and Pathobiology and Institute for Biomaterials and Biomedical Engineering, University of Toronto
*Senior Scientist, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto
Dr. Grynpas has been researching the determinants of bone quality and fragility for the past 30 years. He is also an expert in animal models of bone loss and regeneration. In addition, through his collaborations, he is investigating new calcium phosphate based biomaterials for skeletal tissue engineering.